tbuckley/cabot-search huggingface dataset:
We Can Do Better — Improving Outcomes in the Midst of an Emergency
Authors: Lindsey R. Baden, Eric J. Rubin, Stephen Morrissey, Jeremy J. Farrar, Jeffrey M. Drazen
Journal: New England Journal of Medicine (2017)

On August 8, 2014, the World Health Organization declared the third Public Health Emergency of International Concern in response to the emerging Ebola crisis in Guinea, Liberia, and Sierra Leone. Approximately 20 months later, on March 29, 2016, this emergency was declared over, although many issues remain. After a slow initial response and limited health care resources, traditional epidemic-control measures — in particular, infection-control strategies — were finally able to limit the spread of the disease. But infection control has its limits as well, . . .
Electronic hydraulic lithotripsy by antegrade digital cholangioscopy through endoscopic ultrasound-guided hepaticojejunostomy
Authors: Yasuo Otsuka, Ken Kamata, Mamoru Takenaka, Kosuke Minaga, Hidekazu Tanaka, Masatoshi Kudo
Journal: Endoscopy (2017)

This report describes antegrade electronic hydraulic lithotripsy (Lithotron EL 27; Walz Elektronik, Rohrdorf, Germany) using a digital peroral cholangioscope (SpyGlass DS System; Boston Scientific, Marlborough, Massachusetts, USA) [1] [2] through an endoscopic ultrasound (EUS)-guided hepaticojejunostomy route for common bile duct (CBD) stones ([Video 1]).
An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer
Authors: A. Khairallah, A. Auguste, A. Leary, C. Genestie, P. Pautier, J. Michels, P. Morice, E. Bentivegna, A. Maulard, F. Drusch, S. Mesnage, S. Gouy
Journal: Annals of Oncology (2017)
Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure
Authors: Tania Nevers, Ane M. Salvador, Francisco Velazquez, Njabulo Ngwenyama, Francisco J. Carrillo-Salinas, Mark Aronovitz, Robert M. Blanton, Pilar Alcaide
Journal: The Journal of Experimental Medicine (2017)

Despite emerging data indicating a role for T cells in profibrotic cardiac repair and healing after ischemia, little is known about whether T cells directly impact cardiac fibroblasts (CFBs) to promote cardiac fibrosis (CF) in nonischemic heart failure (HF). Recently, we reported increased T cell infiltration in the fibrotic myocardium of nonischemic HF patients, as well as the protection from CF and HF in TCR-α−/− mice. Here, we report that T cells activated in such a context are mainly IFN-γ+, adhere to CFB, and induce their transition into myofibroblasts. Th1 effector cells selectively drive CF both in vitro and in vivo, whereas adoptive transfer of Th1 cells, opposite to activated IFN-γ−/− Th cells, partially reconstituted CF and HF in TCR-α−/− recipient mice. Mechanistically, Th1 cells use integrin α4 to adhere to and induce TGF-β in CFB in an IFN-γ–dependent manner. Our findings identify a previously unrecognized role for Th1 cells as integrators of perivascular CF and cardiac dysfunction in nonischemic HF.
Decomposition Analysis of Black–White Disparities in Birth Outcomes: The Relative Contribution of Air Pollution and Social Factors in California
Authors: Tarik Benmarhnia, Jonathan Huang, Rupa Basu, Jun Wu, Tim A. Bruckner
Journal: Environmental Health Perspectives (2017)

Racial/ethnic disparities in preterm birth (PTB) are well documented in the epidemiological literature, but little is known about the relative contribution of different social and environmental determinants of such disparities in birth outcome. Furthermore, increased focus has recently turned toward modifiable aspects of the environment, including physical characteristics, such as neighborhood air pollution, to reduce disparities in birth outcomes.To apply decomposition methods to understand disparities in preterm birth (PTB) prevalence between births of non-Hispanic black individuals and births of non-Hispanic white individuals in California, according to individual demographics, neighborhood socioeconomic environment, and neighborhood air pollution.We used all live singleton births in California spanning 2005 to 2010 and estimated PTBs and other adverse birth outcomes for infants borne by non-Hispanic black mothers and white mothers. To compare individual-level, neighborhood-level, and air pollution [Particulate Matter, 2.5 micrometers or less (PM2.5) and nitrogen dioxide (NO2)] predictors, we conducted a nonlinear extension of the Blinder-Oaxaca method to decompose racial/ethnic disparities in PTB.The predicted differences in probability of PTB between black and white infants was 0.056 (95% CI: 0.054, 0.058). All included predictors explained 37.8% of the black-white disparity. Overall, individual (17.5% for PTB) and neighborhood-level variables (16.1% for PTB) explained a greater proportion of the black-white difference in birth outcomes than air pollution (5.7% for PTB).Our results suggest that, although the role of individual and neighborhood factors remains prevailing in explaining black-white differences in birth outcomes, the individual contribution of PM2.5 is comparable in magnitude to any single individual- or neighborhood-level factor. https://doi.org/10.1289/EHP490.
A doença de Lyme crónica e disseminada na Noruega, 1995-2004
Authors: K Nygård, A B Brantsaeter, R Mehl
Journal: Eurosurveillance (2005)

A doenca de Lyme e a mais corrente das infeccoes transmitidas por carracas na Noruega. Todas as manifestacoes clinicas dessa doenca, excluido o eritema migratorio, sao de declaracao obrigatoria ao Folkehelseinstituttet, o instituto noruego de saude publica. Entre 1995 e 2004, foram declarados 1506 casos de doenca de Lyme cronica e disseminada. O diagnostico de laboratorio foi baseado em testes serologicos por quase todos os casos. O numero anual de casos nao indiqua nenhuma tendencia clara para o periodo, mas cada ano, havia entre 120 e 253 casos, com uma incidencia mais grande em 2004. Em 75% dos caso para os quais se disponia da informacao os pacientes mostraram os primeiros sintomas entre junho e outobro. Uma variacao geografica importante e notavel nas taxas de incidencia, provindo as mais altas das zonas costais do sul e centro da Noruega. 56% dos casos eram homens e 44% mulheres. As criancas entre cinco e nove anos eram os mais afetados. A manifestacao clinica mais corrente (71%) era a neuroborreliose, seguida por artritis/artralgia (22%) e acrodermatite cronica atrofiante (5%). Foram hospitalizados 46% dos pacientes. A medidas preventivas contre a borreliose na Noruega consistem em evitar as picadas de carracas protegendo-se com a roupa e usando produtos repelentes, e em detectar precocemente as carracas e arrancalas. Na Noruega, geralmente nao se recomendam os antibioticos como medida profilactica depois de uma picada de carracas.
Influence of HIF-2alpha deregulation and overexpression of VEGF ligands on the response to aflibercept: Identification of predictive biomarkers
Authors: A.K. Larsen, S. Thouroude, L. Louadj, M. Sabbah, E. Dochy, A. de Gramont, J.A. Denis, A. Bouygues
Journal: Annals of Oncology (2017)
Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in advanced gastric cancer: AGAMENON study data
Authors: I. Macias, A. Carmona-Bayonas, M. Ferrer, R. Hernandez, A. Custodio, A. Lacalle, J.E. Lorenzo Barreto, I. Echavarria Diaz-Guardamino, L. Visa, E. Buxo Orra, M. Mangas Izquierdo, A. Azkarate, A. Diaz, A. Viudez, M. Sanchez Canovas, A. Ramchandani Vaswani, F. Longo, E. Martinez de Castro, J. Gallego Plazas, P. Jimenez Fonseca
Journal: Annals of Oncology (2017)
Preserving tumor heterogeneity: A microfluidic reactor for ex vivo preservation of colorectal cancer biopsies
Authors: G.A. Llamazares, C. Sostres, A.E. Vigueras, A. Lué, J.L. Calavia, C. Alcaine, R. Guerrero, A.G. Gonzales, M.T. Ramírez, A. Lacueva, S. González, A. Lanas, I. Ochoa, L.J. Fernández
Journal: Annals of Oncology (2017)
The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer
Authors: C. Ordu, K.N. Pilancı, F. Elbüken, G. Alço, Ü.İ. Köksal, S. İlgün, D. Sarsenov, A.E. Aydın, A. Öztürk, Z.İ. Erdoğan, F. Ağaçayak, C. Tecimer, Y. Eralp, F. Aktepe, V. Özmen
Journal: Annals of Oncology (2017)
Mechanism of pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/fluorouracil/leucovorin/bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC)
Authors: S. Goel, A. Ocean, I. Chaudhary, M.H. Ghalib, E. Kaledzi, U. Shah, A.A. Gutierrez, M. Coffey, G. Gill, R. Maitra
Journal: Annals of Oncology (2017)
Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When Is the Most Clinically Relevant Time to Evaluate?
Authors: Marin Nishimura, Isac Thomas, Jonathan C. Hsu
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
Authors: J. Tabernero, R.R. Hozak, T. Yoshino, A.L. Cohn, R. Obermannova, G. Bodoky, R. Garcia-Carbonero, T.-E. Ciuleanu, D.C. Portnoy, J. Prausová, K. Muro, R.W. Siegel, R.J. Konrad, H. Ouyang, S.A. Melemed, D. Ferry, F. Nasroulah, E. Van Cutsem
Journal: Annals of Oncology (2017)

The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. To identify patients who benefit the most from VEGFR-2 blockade, the RAISE trial design included a prospective and comprehensive biomarker program that assessed the association of biomarkers with ramucirumab efficacy outcomes.
Phase II study of pre-operative panitumumab and external pelvic radiotherapy (RT) in locally advanced rectal cancer (LARC) patients (pts) (RaP/STAR-03 Study): Preliminary report of safety and treatment compliance.
Authors: Carmine Pinto, Francesca Di Fabio, Maurizio DI Bisceglie, Tiziana Pia Latiano, Anna Maria Bochicchio, Gerardo Rosati, Stefano Sergio Cordio, Antonella Marino, Sara Lonardi, Carlo Aschele, Stefania Giaquinta, Daniela Baldari, Luca Boni
Journal: Journal of Clinical Oncology (2015)

e14502 Background: The treatment with fluoropyrimidines and concomitant RT is the standard care inLARC preoperative chemoradiation. The aim of RaP/STAR-03 study is to evaluate the activity and safety of panitumumab single agent in LARC preoperative treatment. Methods: RaP/STAR-03 is a phase II study with panitumumab and concomitant RT followed by TME surgery and adjuvant chemotherapy (ACT) in LARC pts. The inclusion criteria are: diagnosis of adenocarcinoma of the mid-low rectum; KRAS wild-type; stage cT3N-M0 or cT2-T3N+M0; CRM-. Panitumumab is administered by IV infusion at a dose of 6 mg/kg once Q2W for 3 cycles concomitant to RT delivered up to a dose of 50.4 Gy in daily fractions of 1.8 Gy (day 1-38). Rectal surgery is performed 6-8 weeks after the end of pre-operative treatment. ACT regimen is FOLFOX4 (12 cycles). Primary end-point is pCR rate. The sample size is calculated using Simon's two-stage design. A pCR of 16% is considered to qualify the experimental treatment for further testing. The first stage requires at least 3 pts of 29 to have a confirmed pCR. In the second stage 63 assessable pts are added. Results: The first-stage of statistical design is achieved, and from October 2012 to January 2015 67/92 pts have been enrolled in 12 centers. The safety data and treatment compliance of the first 55 pts are reported. Pt characteristics were: M 37(67.3%), F18 (32.7%), median age 65 years (45-84); cT3 47(87.3%), cN+ 27(49.1%). G3 toxicities were observed in 8(14.6%) pts; no G4 toxicities were reported. The median panitumumab treatment was 3 infusions. The RT compliance was: median dose 50.4 Gy; ≥ 28 fractions 36(65.5%) pts. The main toxicities for pt were: anemia G1-2 1(1.8%), G3 1(1.8%); leucopenia G1 3(5.5%); thrombocytopenia G1 3(5.5%); diarrohea G1-2 15(27.3%); skin rash G1-2 44(80%), G3 7(12.7%), radiodermatitis G1 3(5.5%); proctitis G1-2 2(3.6%). Intra-operative complications were observed in 2(3.6%) pts and post-operative in 5(9.9%). Conclusions: This preliminary analysis shows a good toxicity profile and compliance to concomitant administration of panitumumab and RT in preoperative treatment of LARC. Clinical trial information: EUDRACT.
Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study
Authors: Stéphane Verguet, Carlos Riumallo-Herl, Gabriela B Gomez, Nicolas A Menzies, Rein M G J Houben, Tom Sumner, Marek Lalli, Richard G White, Joshua A Salomon, Ted Cohen, Nicola Foster, Susmita Chatterjee, Sedona Sweeney, Inés Garcia Baena, Knut Lönnroth, Diana E Weil, Anna Vassall
Journal: The Lancet Global Health (2017)

The economic burden on households affected by tuberculosis through costs to patients can be catastrophic. WHO's End TB Strategy recognises and aims to eliminate these potentially devastating economic effects. We assessed whether aggressive expansion of tuberculosis services might reduce catastrophic costs.We estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis services in India and South Africa from 2016 to 2035, in line with the End TB Strategy. Using modelled incidence and mortality for tuberculosis and patient-incurred cost estimates, we investigated three intervention scenarios: improved treatment of drug-sensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of access to tuberculosis care through intensified case finding (South Africa only). We defined tuberculosis-related catastrophic costs as the sum of direct medical, direct non-medical, and indirect costs to patients exceeding 20% of total annual household income. Intervention effects were quantified as changes in the number of households incurring catastrophic costs and were assessed by quintiles of household income.In India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number of households incurring tuberculosis-related catastrophic costs by 6-19%. The benefits would be greatest for the poorest households. In South Africa, expanded access to care could decrease household tuberculosis-related catastrophic costs by 5-20%, but gains would be seen largely after 5-10 years.Aggressive expansion of tuberculosis services in India and South Africa could lessen, although not eliminate, the catastrophic financial burden on affected households.Bill & Melinda Gates Foundation.
FPA150, a novel B7-H4 therapeutic antibody with checkpoint blockade and ADCC activities
Authors: C.D. Kaplan, D. Houser, F. Kemp, N. Nielson, A. Hsu, K. Legris, G. Brattich, H. Xiang, A. Ahene, U. Jeffry, D. Bellovin, L. Borges
Journal: Annals of Oncology (2017)
Baseline neutrophil-to-lymphocyte ratio and its values monitored over time is associated with outcome of metastatic melanoma patients treated with immunotherapy
Authors: I. Lugowska, B. Cybulska-Stopa, P. Jagodzinska-Mucha, P. Teterycz, H. Koseła-Paterczyk, K. Kozak, K. Szamotulska, K. Roman, T. Switaj, M. Ziobro, P. Rutkowski
Journal: Annals of Oncology (2017)
Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial
Authors: K. Khan, D. Cunningham, G. Vlachogiannis, S. Hedayat, M. Rata, D-M. Koh, N. Tunariu, Y. Jamin, D. Collins, I. Chau, S. Rao, D. Watkins, N. Starling, C. Peckitt, N. Fotiadis, C. Saffery, J. Hahne, M. Fassan, C. Braconi, N. Valeri
Journal: Annals of Oncology (2017)
Use and Outcomes of Kidneys from Donation after Circulatory Death Donors in the United States
Authors: John Gill, Caren Rose, Julie Lesage, Yayuk Joffres, Jagbir Gill, Kevin O’Connor
Journal: Journal of the American Society of Nephrology (2017)

Donation after circulatory death (DCD) donors are an important source of kidneys for transplantation, but DCD donor transplantation is less common in the United States than in other countries. In this study of national data obtained between 2008 and 2015, recovery of DCD kidneys varied substantially among the country's 58 donor service areas, and 25% of DCD kidneys were recovered in only four donor service areas. Overall, 20% of recovered DCD kidneys were discarded, varying from 3% to 33% among donor service areas. Compared with kidneys from neurologically brain dead (NBD) donors, DCD kidneys had a higher adjusted odds ratio of discard that varied from 1.25 (95% confidence interval [95% CI], 1.16 to 1.34) in kidneys with total donor warm ischemic time (WIT) of 10-26 minutes to 2.67 (95% CI, 2.34 to 3.04) in kidneys with total donor WIT >48 minutes. Among the 12,831 DCD kidneys transplanted, kidneys with WIT≤48 minutes had survival similar to that of NBD kidneys. DCD kidneys with WIT>48 minutes had a higher risk of allograft failure (hazard ratio, 1.23; 95% CI, 1.07 to 1.41), but this risk was limited to kidneys with cold ischemia time (CIT) >12 hours. We conclude that donor service area-level variation in the recovery and discard of DCD kidneys is large. Additional national data collection is needed to understand the potential to increase DCD donor transplantation in the United States. Strategies to minimize cold ischemic injury may safely allow increased use of DCD kidneys with WIT>48 minutes.
Impacts of the Human Gut Microbiome on Therapeutics
Authors: Yoshiki Vázquez-Baeza, Chris Callewaert, Justine Debelius, Embriette Hyde, Clarisse Marotz, James T. Morton, Austin Swafford, Alison Vrbanac, Pieter C. Dorrestein, Rob Knight
Journal: The Annual Review of Pharmacology and Toxicology (2017)

The human microbiome contains a vast source of genetic and biochemical variation, and its impacts on therapeutic responses are just beginning to be understood. This expanded understanding is especially important because the human microbiome differs far more among different people than does the human genome, and it is also dramatically easier to change. Here, we describe some of the major factors driving differences in the human microbiome among individuals and populations. We then describe some of the many ways in which gut microbes modify the action of specific chemotherapeutic agents, including nonsteroidal anti-inflammatory drugs and cardiac glycosides, and outline the potential of fecal microbiota transplant as a therapeutic. Intriguingly, microbes also alter how hosts respond to therapeutic agents through various pathways acting at distal sites. Finally, we discuss some of the computational and practical issues surrounding use of the microbiome to stratify individuals for drug response, and we envision a future where the microbiome will be modified to increase everyone's potential to benefit from therapy.
TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study
Authors: M. Sinn, J. Budczies, F. Damm, P. Lohneis, R. Schmuck, D. Treue, J.K. Striefler, M. Bahra, U. Pelzer, A. Jühling, H. Bläker, S. Bischoff, H. Oettle, C. Denkert, H. Riess, B. Sinn
Journal: Annals of Oncology (2017)
Body mass index (BMI), lifestyle behaviors, and perceptions in cancer survivors
Authors: L. Eng, S. Su, D. Pringle, M. Mahler, C. Niu, H. Naik, R. Mohan, K. Tiessen, H. Hon, C.M. Brown, J.M. Jones, D. Howell, P. Selby, S. Alibhai, W. Xu, G. Liu
Journal: Annals of Oncology (2017)
International Incidence of Complications After Catheter Ablation of Persistent Atrial Fibrillation (AF): Insights From the Multicenter, Prospective, Randomized STAR AF II Trial
Authors: A Verma, J Chen-yang, T Betts, J Chen, I Delsenhofer, R Mantovan, L Macle, C Morillo, P Sanders
Journal: Circulation (2013)
Práticas sexuais e transmissão das hepatites A e C
Authors: E Bouvet
Journal: Eurosurveillance (2005)

Na presente edicao da Eurosurveillance, dois artigos relatam a ocurencia de surtos de hepatites virais A (em Copenhague) [1] e C (em Paris) [2] na populacao homosexual masculina para a qual praticas sexuais especificas tem sido evocadas como modo de transmissao. 
Desde decadas, tem-se pensado que o virus da hepatite A (VHA) e transmitido directamente de pessoa a pessoa por via fecal-oral ou por meio de comidas contaminadas (inicialmente ou durante a preparacao) enquanto que o da hepatite C (VHC) se transmete por via parenteral (pelo sangue e seus derivados). No que diz respeito a hepatite A, varios surtos ja foram relatados em homosexuais que levarem a recomendacoes para a vaccinacao contre a hepatite A feitas pelas autoridades sanitarias de varios paises [3,4].
Clinical and dermoscopic characterization of pediatric and adolescent melanomas: Multicenter study of 52 cases
Authors: Cristina Carrera, Alon Scope, Stephen W. Dusza, Giuseppe Argenziano, Gianluca Nazzaro, Alice Phan, Isabelle Tromme, Pietro Rubegni, Josep Malvehy, Susana Puig, Ashfaq A. Marghoob
Journal: Journal of the American Academy of Dermatology (2017)
Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study
Authors: D. Zandberg, A. Algazi, A. Jimeno, J.S. Good, J. Fayette, N. Bouganim, N. Ready, P.M. Clement, T. Goswmi, A. Jarkowski, J.M. Armstrong, K. Asubonteng, G. Melillo, R. Mesía
Journal: Annals of Oncology (2017)
Preliminar analysis of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): NORA trial (GECP 15/02)
Authors: M. Majem Tarruella, L. Isla Casado, M. Guirado, B. Massuti Sureda, A.L. Ortega Granados, R. Marse Fabregat, M. Domine Gomez, R. de las Peñas, M.T. Moran Bueno, S. Vazquez Estevez, M.A. Sala Gonzalez, J. Coves Sarto, J.M. Sánchez-Torres, D. Vicente Baz, J. Gonzalez-Larriba, A. Paredes, N. Farré, L. Fernández Fornos, A. Mena, M. Provencio Pulla
Journal: Annals of Oncology (2017)